Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04568083 · ClinicalTrials.gov registry record
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 7,035
- Enrollment target
NCT04568083 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 7,035 participants.
The verdict
NCT04568083 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 7,035 participants
- Enrollment target
Study Summary
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany). The study will include patients initiating treatment with ticagrelor 60 mg after a myocardial infarction in real-world clinical practice, and describe their patient characteristics and duration of treatment. If the a priori threshold of 5,000 person-years on treatment with ticagrelor 60 mg is met, outcome events (bleeding and cardiovascular events) will also be analysed and described.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,035 participants |
| Start Date | 2020-09-25 |
| Est. Completion | 2021-06-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04568083
The ClinicalTrials.gov registry entry for NCT04568083 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,035 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04568083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04568083 about?
NCT04568083 is a clinical study titled "Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice". This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany). The study will include patients initiating treatment with ticagrelor 60 mg after a myocardial infarction in real-world clinical pr...
What is the current status of trial NCT04568083?
This trial is currently completed. The enrollment target is 7,035 participants. The study started on 2020-09-25. Estimated completion is 2021-06-28.
Who is sponsoring clinical trial NCT04568083?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.